Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

15P - Modified sialoglycan by neuraminidase promotes tumor immunity against epithelial ovarian cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Immunology

Tumour Site

Ovarian Cancer

Presenters

Huang mei

Citation

Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684

Authors

H.J. mei1, M. Li2, G. Zhang3, Y. Zhu4, J. Huang2

Author affiliations

  • 1 School Of Medicine, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China, 610041 - Chengdu/CN
  • 2 Biochemistry And Molecular Biology, Sichuan Cancer Institute, 610041 - Chengdu/CN
  • 3 Department Of Gynecologic Oncology, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China, 610041 - Chengdu/CN
  • 4 Department Of Ultrasound, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 15P

Background

Sialoglycan with α-2,3-linked/α-2,6-linked sialic acid (Sia) on the cancer cell surface protects cancer cell from immunologic recognition. Binding of α-galactose/α-N-acetylgalactosamine (Gal/GalNAc) epitope to macrophage galactose type C-lectin receptor (MGL) improves dendritic cell (DC) performance. We identified if modified sialoglycan by neuraminidase (NA) stimulates cellular immune response to EOC.

Methods

Sialoglycan on human EOC OVCAR3, A2780 and mouse ID8 cells was hydrolyzed with α2,6NA. NA-treated and NA-untreated OVCAR3 and A2780 cells were incubated with immature DC (imDC) to achieve NA-DC and nonNA-DC. Human peripheral blood lymphocytes (PBL) were stimulated with NA-DC and nonNA-DC. Gal/GalNAc and α-2,6Sia epitope of EOC cells, phenotypes of DCs and PBL were measured with flow cytometry (FCM); IFN-γ expression by PBL was determined by RT-qPCR; cytotoxicity of PBL to OVCAR3 and A2780 cells were detected by using LDH release assay. NA-treated and NA-untreated ID8 cells were vaccinated subcutaneously in the right axilla of C57 mice once per week for 3 consecutive weeks, then parental ID8 cells were inoculated in the opposite axilla. The tumor growth was observed; IFN-γ of plasm was tested by ELISA.

Results

α-2,6Sia (Sambucus Nigra Lectin, SNA) decreased and Gal/GalNAc (Peanut Agglutinin, PNA) increased in the NA-treated OVCAR3, A2780 and ID8 cells. MGL, CD83 and CD86 on NA-DCs increased significantly; Siglec-9 on NA-DCs and nonNA-DCs for A2780 not OVCAR3 cells decreased markedly compared to imDCs. PBL stimulated with NA-DCs had a higher expression of IFN-γ and CD69 than PBL stimulated with nonNA-DCs did. PBL stimulated with NA-DCs for A2780 but not for OVCAR3 cells showed an enhanced cytotoxicity; the cytotoxicity of PBL stimulated with NA-DCs was slightly higher than that of PBL stimulated with nonNA-DCs for OVCAR3 cells. Tumorigenesis was reduced significantly in the vaccinated mice with NA-treated ID8 cells; the plasm level of IFN-γ was significantly increased in the vaccinated mice.

Conclusions

NA modified sialoglycan structure could promote immune response to EOC.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.